Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Authors
Keywords
-
Journal
npj Breast Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-16
DOI
10.1038/s41523-021-00252-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival
- (2020) Paul W Sperduto et al. NEURO-ONCOLOGY
- Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
- (2020) Elise Deluche et al. EUROPEAN JOURNAL OF CANCER
- Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
- (2020) Zheng Hu et al. NATURE GENETICS
- Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
- (2020) Rong Chen et al. MODERN PATHOLOGY
- Rhabdomyosarcoma
- (2019) Stephen X. Skapek et al. Nature Reviews Disease Primers
- The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
- (2019) David Pérol et al. BMJ Open
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
- (2019) Lindsay Angus et al. NATURE GENETICS
- Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
- (2019) Johan Staaf et al. NATURE MEDICINE
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
- (2018) William J. Gradishar et al. Journal of the National Comprehensive Cancer Network
- Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
- (2018) Hajime Kuroda et al. Breast Cancer
- Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?
- (2017) Niamh M. Foley et al. PATHOLOGY & ONCOLOGY RESEARCH
- Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group
- (2016) Syed Salahuddin Ahmed et al. JOURNAL OF CLINICAL PATHOLOGY
- Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
- (2014) Frédérique Penault-Llorca et al. ANNALES DE PATHOLOGIE
- Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014
- (2014) Gaëtan MacGrogan et al. ANNALES DE PATHOLOGIE
- Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis
- (2014) Arkadiusz Gertych et al. Diagnostic Pathology
- An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer
- (2013) Jose A. Pérez-Fidalgo et al. BREAST
- A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
- (2013) Gaetano Aurilio et al. EUROPEAN JOURNAL OF CANCER
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Mise à jour des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
- (2010) Frédérique Penault-Llorca et al. ANNALES DE PATHOLOGIE
- Stability of estrogen receptor status in breast carcinoma
- (2010) Yun Gong et al. CANCER
- Quality Improvement Guidelines for Percutaneous Needle Biopsy
- (2010) Sanjay Gupta et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Immunohistochemically Determined Estrogen Receptor Phenotype Remains Stable in Recurrent and Metastatic Breast Cancer
- (2008) Carmen Gomez-Fernandez et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started